To develop pancreatic cancer (PC) therapy efficiently and safely, preclinical testing stands as an indispensable step in the process. Embracing a steadfast dedication to advancing precision oncology therapies, Alfa Cytology unequivocally pledges to deliver an extensive and comprehensive range of preclinical testing services.
Introduction to Preclinical Stages
Preclinical services for PC therapy play a critical role in developing effective therapies. These services bridge the gap between laboratory research and clinical trials, providing essential data to evaluate new therapeutic agents' pharmacodynamic, pharmacokinetic, and safety.
Preclinical services encompass various in vitro and in vivo studies. In vitro studies utilize cancer cell lines to assess the cytotoxic effects of potential compounds, evaluate dose-response relationships, and identify potential biomarkers for sensitivity or resistance. Following promising in vitro results, in vivo studies are conducted using animal models to analyze pharmacokinetics, pharmacodynamics, and toxicology. These studies help determine the therapeutic window and optimal dosing regimens, which are crucial for subsequent trial design.
Fig. 1 Schematic of the drug discovery process and the main contents of preclinical research. (Wu F.; et al., 2020)
Another vital aspect of preclinical services is the exploration of combination therapies. Given the complexity of cancer, evaluating the synergistic effects of multiple drugs can lead to more effective treatment strategies.
Our Services
Preclinical testing greatly reduces the failure rate of human testing and avoids high costs. Alfa Cytology provides one-stop or modular preclinical testing services and handles both small-molecule and large-molecule services across various complex technology platforms and niche technologies for PC therapies. Our preclinical testing includes evaluating candidate drugs using in vitro and in vivo platforms.
Alfa Cytology provides pharmacodynamic studies to quantify the strength of the effect and determine whether a drug candidate is effective.
- Dose range finding
- Maximal tolerability dose
- Cytotoxicity
- Hematology
Understanding the pharmacokinetics properties is essential to drug development. Alfa Cytology offers a variety of PK Assessment services.
Alfa Cytology specializes in using a range of assays to identify the potential toxicity of drugs to different tissues and organs.
- High-throughput toxicity screening
- High-content toxicity screening
- Hepatotoxicity
- Cardiotoxicity
Why Choose Us?
Advantages
Customized Solutions
Scientific Excellence
Collaborative Approach
DataSecurity Worldwide Service
Overall, preclinical services are essential for identifying promising cancer therapies, minimizing clinical trial risks, and advancing new treatments from the lab to the clinic. Through rigorous preclinical testing and validation, Alfa Cytology's services not only enhance the understanding of cancer biology but also pave the way for innovative therapeutic approaches. If you have any questions about our PC preclinical services, please feel free to contact us.
Reference
- Wu F, et al. Computational Approaches in Preclinical Studies on Drug Discovery and Development. Front Chem. 2020;8:726. Published 2020 Sep 11. doi:10.3389/fchem.2020.00726
